Vanda Pharmaceuticals (VNDA) Receives Buy Rating from Seaport Global Securities
Seaport Global Securities reissued their buy rating on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research note published on Wednesday. Seaport Global Securities currently has a $21.00 price objective on the biopharmaceutical company’s stock. Seaport Global Securities also issued estimates for Vanda Pharmaceuticals’ Q2 2018 earnings at $0.02 EPS, Q3 2018 earnings at $0.02 EPS and Q4 2018 earnings at $0.11 EPS.
A number of other brokerages have also issued reports on VNDA. BidaskClub upgraded shares of Vanda Pharmaceuticals from a hold rating to a buy rating in a report on Wednesday, February 21st. Oppenheimer set a $27.00 price objective on shares of Vanda Pharmaceuticals and gave the company a buy rating in a report on Thursday, February 15th. Jefferies Group reiterated a buy rating and issued a $20.00 price objective on shares of Vanda Pharmaceuticals in a report on Tuesday, February 13th. Finally, ValuEngine upgraded shares of Vanda Pharmaceuticals from a sell rating to a hold rating in a report on Wednesday, December 20th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of Buy and an average target price of $21.57.
Vanda Pharmaceuticals (VNDA) opened at $19.00 on Wednesday. The stock has a market cap of $867.32, a P/E ratio of -54.29 and a beta of 1.02. Vanda Pharmaceuticals has a fifty-two week low of $11.90 and a fifty-two week high of $19.70.
In other Vanda Pharmaceuticals news, SVP Gunther Birznieks sold 8,525 shares of the firm’s stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $18.72, for a total transaction of $159,588.00. Following the completion of the transaction, the senior vice president now owns 148,366 shares in the company, valued at approximately $2,777,411.52. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Mihael Hristos Polymeropoulos sold 191,760 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $15.30, for a total transaction of $2,933,928.00. Following the transaction, the insider now owns 1,031,848 shares of the company’s stock, valued at approximately $15,787,274.40. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 287,506 shares of company stock valued at $4,665,795. Company insiders own 7.60% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the business. Teacher Retirement System of Texas bought a new position in Vanda Pharmaceuticals during the 4th quarter worth approximately $209,000. Metropolitan Life Insurance Co. NY bought a new position in Vanda Pharmaceuticals during the 4th quarter worth approximately $221,000. Los Angeles Capital Management & Equity Research Inc. bought a new position in Vanda Pharmaceuticals during the 3rd quarter worth approximately $277,000. MetLife Investment Advisors LLC bought a new position in Vanda Pharmaceuticals during the 4th quarter worth approximately $308,000. Finally, Voya Investment Management LLC raised its holdings in Vanda Pharmaceuticals by 29.7% during the 2nd quarter. Voya Investment Management LLC now owns 20,118 shares of the biopharmaceutical company’s stock worth $328,000 after purchasing an additional 4,605 shares during the last quarter. Hedge funds and other institutional investors own 89.13% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Vanda Pharmaceuticals (VNDA) Receives Buy Rating from Seaport Global Securities” was posted by Daily Political and is the property of of Daily Political. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://www.dailypolitical.com/2018/03/03/vanda-pharmaceuticals-vnda-receives-buy-rating-from-seaport-global-securities.html.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.